Over three decades of research on Crohn's disease, a question that rarely draws attention has quietly grown into a problem of measurement: how often does the upper digestive tract become involved in adults, and how often is anyone actually looking? A scoping review led by investigators at Western University, published in the Journal of Crohn's and Colitis, gathers 117 studies and eight systematic reviews to show that the answer shifts with the method of the search itself. The field's uncertainty, in this telling, is less a mystery of the body than a reflection of inconsistent labels and uneven
Scoping Review Finds Adult Upper GI Crohn's Disease Prevalence Varies Widely, Calls for Standard Definitions
Over three decades of research on Crohn's disease, a question that rarely draws attention has quietly grown into a problem of measurement: how often does the upper digestive tract become involved in adults, and how often is anyone actually looking? A scoping review led by investigators at Western University, published in the Journal of Crohn's and Colitis, gathers 117 studies and eight systematic reviews to show that the answer shifts with the method of the search itself. The field's uncertainty, in this telling, is less a mystery of the body than a reflection of inconsistent labels and uneven examination, and the path toward clearer knowledge runs through agreeing on shared definitions and how to look.
A team at Western University in Ontario has reviewed three decades of research on upper gastrointestinal Crohn's disease in adults, a corner of the condition that rarely receives top billing. Their scoping review, published in the Journal of Crohn's and Colitis, drew on studies from 1995 through November 2025 and found that the numbers depend heavily on how patients were classified and how carefully they were examined.
Upper GI involvement is well documented in children with Crohn's, but in adults it is widely believed to be underestimated. The researchers pointed to two culprits: inconsistent definitions across studies, and endoscopy that was often used selectively, so only some patients were ever examined. Across 95 usable patient cohorts, the median prevalence came to 8.8%, though estimates ranged widely, from 3.99% to 14.5% across the middle half. Cohorts that used systematic endoscopy and biopsy found more disease than those drawn from population-based samples.
Isolated upper GI disease, with no involvement elsewhere in the digestive tract, was far rarer, with a median of 1.37%. Estimates also shifted by region and ethnicity, though the review could not explain why. Reporting of specific anatomical sites was inconsistent, and few studies recorded risk factors such as smoking or family history, limiting what can be said about who is most at risk.
The authors' remedy is procedural: standardized, site-specific adult definitions and systematic diagnostic protocols. Such steps, they argue, would allow fairer comparison across studies and sharpen future estimates. Until then, the 8.8% median is best understood as a rough center of a very scattered picture.
A team at Western University in Ontario has gone back through three decades of research on a corner of Crohn's disease that rarely gets top billing, and what they found is a field in which the numbers depend heavily on how, and whether, anyone looked. Their scoping review, published in the Journal of Crohn's and Colitis, centers on upper gastrointestinal Crohn's disease in adults.
Upper GI involvement is commonly observed in children with Crohn's. In adults, the researchers wrote, it is underestimated. They pointed to two reasons for the uncertainty: classification of the disease has been inconsistent from study to study, and endoscopy has often been used selectively, meaning only some patients were examined. Both, they said, have contributed to variable prevalence estimates.
To map what is known and what is missing, the investigators searched three databases: Embase, Cochrane CENTRAL, and MEDLINE. They included studies with data from 1995 through November 2025 that reported prevalence and epidemiologic information on adults with upper GI Crohn's disease. The review followed PRISMA-ScR and JBI methodology. From each eligible study, the team pulled estimated prevalence, which sites were involved, and demographic details.
In all, the review included 117 primary studies and eight systematic reviews. Together they contained 95 patient cohorts with usable prevalence data. Across those cohorts, the median prevalence of adult upper GI Crohn's disease was 8.8%, with an interquartile range of 3.99% to 14.5%. That spread is wide, and the pattern behind it was telling: cohorts that used systematic endoscopy and biopsy found more disease than population-based cohorts did.
Isolated upper GI disease, meaning cases without involvement elsewhere, was far less common. Its median prevalence was 1.37%, a figure the authors described as rare.
The estimates also shifted by geography and ethnicity. Cohorts with South Asian patients showed lower rates, while cohorts with East Asian and Middle Eastern patients showed higher ones. The review did not settle why. It did note that reporting of specific anatomical sites was inconsistent, and that few studies included modifier data such as smoking or family history of adult upper GI Crohn's disease, both gaps that limit how much can be said about who is most at risk.
The authors concluded that prevalence estimates over the three decades were highly variable because of inconsistent definitions and detection strategies. Their remedy is procedural rather than clinical: standardized, site-specific adult definitions and systematic diagnostic protocols. Such measures, they wrote, would allow comparison across studies, improve prevalence estimates, and address the demographic reporting gaps. Until studies define and detect the disease the same way, the 8.8% median is best read as a rough center of a very scattered picture.
Vuoi la storia completa?
Leggi l'originale su DocWireNews ↗
Health & Medicine